Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog).
A group of 13 acromegalic patients was treated with lanreotide for 18 months and followed-up echocardiographically; these patients showed significant correlations between the decrease of both growth hormone (GH) and insulin-like growth factor-1 and the decrease of left ventricular mass index. This documents a regression of left ventricular hypertrophy in acromegaly after lanreotide treatment, the degree of which is dependent on the magnitude of the decrease of GH and insulin-like growth factor-1 serum levels.
Hradec
J
J
Third Department of Medicine, Charles University, Prague, Czech Republic.
Kral
J
J
Janota
T
T
Krsek
M
M
Hana
V
V
Marek
J
J
Malik
M
M
D000172:Acromegaly / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D005260:Female; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000188:drug therapy* / Q000209:etiology; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D006727:Hormone Antagonists; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin